Form 4: RA Capital Management Reports Beneficial Ownership Changes in Bicara Therapeutics Following IPO

RA Capital Management and related entities report changes in beneficial ownership of Bicara Therapeutics (BCAX) common stock following the company's initial public offering, including conversion of preferred stock and open market purchases.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund III, L.P., Peter Kolchinsky, and Rajeev Shah, filed a Form 4 detailing changes in beneficial ownership of Bicara Therapeutics Inc. (BCAX) common stock.
• The changes occurred on September 16, 2024, and are primarily due to the conversion of Series B and Series C preferred stock into common stock upon the closing of Bicara Therapeutics' initial public offering (IPO).
• The preferred stock converted at a rate of one share of preferred stock for 9.2435 shares of common stock.
• RA Capital also purchased 1,680,520 shares at $18 and 152,480 shares at $18.
• After the reported transactions, RA Capital Management and related entities beneficially own 4,303,418 shares and 2,652,575 shares indirectly through the Fund and Nexus Fund III respectively.
• RA Capital Management, L.P. is the investment manager for RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P.
• Peter Kolchinsky and Rajeev Shah are managing members of RA Capital Management GP, LLC, the general partner of the Adviser.
• Each of the reporting persons disclaims beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard post-IPO transactions and insider confidence through stock purchases. There are no explicit negative indicators.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of Bicara Therapeutics following its IPO.
• RA Capital's continued investment, including the purchase of 1,680,520 shares at $18 and 152,480 shares at $18, signals confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice for significant shareholders following material transactions in a company's stock, particularly after events like an IPO. This filing provides transparency into the ownership structure of Bicara Therapeutics.

Stakeholder Impact

• The filing provides transparency to shareholders regarding the ownership structure of the company.
• The stock purchases by RA Capital may be viewed positively by the market.

Key Dates